Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
The awards vest over multiple years, with continued employment required through each applicable vesting date.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Spero Therapeutics (SPRO) granted equity awards to new employees on October 1, 2026, under its 2019 Inducement Equity Incentive Plan.
The Compensation Committee approved 233,000 restricted stock units (RSUs) and 323,000 stock options as employment inducements under Nasdaq Listing Rule 5635(c)(4). Shares underlying the options vest 25% on the first anniversary of each employee’s start date, with the remainder vesting in 36 equal monthly installments thereafter. RSUs vest in four equal annual installments beginning on that first anniversary. Both schedules require continued employment through the applicable vesting dates.
Positive
- None.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.233,000 RSUs and 323,000 stock options granted to new employees create potential shareholder dilution as awards vest.
Key Figures
- Restricted stock unit awards
- 233,000 RSUs
- Aggregate inducement grants to new employees
- Stock options
- 323,000 options
- Aggregate inducement grants to new employees
- Initial option vesting
- 25%
- Vests on the first anniversary of the employee’s start date
- Remaining option vesting
- 36 equal monthly installments
- After the initial vesting, subject to continued employment
- RSU vesting
- 4 equal annual installments
- Beginning on the first anniversary of the employee’s start date
Historical Context
-
Granted RSUs and options to new employees under the 2019 Inducement Plan.
-
Granted stock options and RSUs to a new employee under the 2019 Inducement Plan.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
restricted stock unit financial
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced that the Compensation Committee of Spero’s Board of Directors approved grants, made on October 1, 2026, of an aggregate of 233,000 restricted stock unit awards (RSUs) and 323,000 stock options to new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended (2019 Inducement Plan). The stock options and RSUs are being granted as an inducement material to Spero’s new employees in accordance with Nasdaq Listing Rule 5635(c)(4).
The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Spero (or following a bona fide period of non-employment), as a material inducement for such individuals entering into employment with Spero, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
The shares underlying the options vest as to
About Spero Therapeutics
Spero Therapeutics is a clinical-stage biopharmaceutical company focused on advancing next-generation medicines for patients with serious immune-mediated diseases. The company’s lead program, SP001, is a third-generation, Fc-silent anti-CD40L monoclonal antibody being advanced first in IgG4-related disease, with potential for development in additional immunological and inflammatory diseases. For more information, visit www.sperotx.com
Investor Relations Contact:
Shai Biran, PhD
Spero Therapeutics
IR@Sperotx.com
Media Inquiries:
media@sperotx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity awards did Spero Therapeutics grant to new employees on October 1, 2026?
Spero granted 233,000 restricted stock units and 323,000 stock options to new employees. The Compensation Committee approved the awards under the 2019 Inducement Equity Incentive Plan as employment inducements under Nasdaq Listing Rule 5635(c)(4).
How do Spero Therapeutics’ October 1, 2026 inducement awards vest?
Shares underlying the options vest 25% on the first anniversary of each employee’s start date, with the remainder in 36 equal monthly installments thereafter. RSUs vest in four equal annual installments beginning on that first anniversary. Both require continued employment through the applicable vesting dates.